Compounds useful as kinase inhibitors
US-2019000806-A1 · Jan 3, 2019 · US
Compounds useful as kinase inhibitors
US10342780B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10342780-B2 |
| Application number | US-201816109162-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 22, 2018 |
| Priority date | Dec 16, 2015 |
| Publication date | Jul 9, 2019 |
| Grant date | Jul 9, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound selected from the group consisting of: or a pharmaceutically acceptable salt thereof. 2. The compound of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 3. The compound of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 4. The compound of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 5. The compound of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 6. The compound of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 7. The compound of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 8. The compound of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 9. The compound of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 10. The compound of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 11. The compound of claim 1 , wherein the compound is selected from the group consisting of: 12. The compound of claim 1 , wherein the compound is in the form of a pharmaceutically acceptable salt. 13. A pharmaceutical composition comprising a compound selected from the group consisting of: or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient. 14. The pharmaceutical composition of claim 13 , wherein the compound is or a pharmaceutically acceptable salt thereof. 15. The pharmaceutical composition of claim 13 , wherein the compound is or a pharmaceutically acceptable salt thereof. 16. The pharmaceutical composition of claim 13 , wherein the compound is or a pharmaceutically acceptable salt thereof. 17. The pharmaceutical composition of claim 13 , wherein the compound is or a pharmaceutically acceptable salt thereof. 18. The pharmaceutical composition of claim 13 , wherein the compound is or a pharmaceutically acceptable salt thereof. 19. The pharmaceutical composition of claim 13 , wherein the compound is or a pharmaceutically acceptable salt thereof. 20. The pharmaceutical composition of claim 13 , wherein the compound is or a pharmaceutically acceptable salt thereof. 21. The pharmaceutical composition of claim 13 , wherein the compound is or a pharmaceutically acceptable salt thereof. 22. The pharmaceutical composition of claim 13 , wherein the compound is or a pharmaceutically acceptable salt thereof. 23. The pharmaceutical composition of claim 13 , wherein the compound is selected from the group consisting of: 24. The composition of claim 13 , wherein the compound is in the form of a pharmaceutically acceptable salt.
Assignees
Inventors
Classifications
directly linked by a ring-member-to-ring-member bond · CPC title
linked by a carbon chain containing only aliphatic carbon atoms · CPC title
containing three or more hetero rings · CPC title
linked by a carbon chain containing alicyclic rings · CPC title
linked by a carbon chain containing only aliphatic carbon atoms · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10342780B2 cover?
- This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immun…
- Who is the assignee on this patent?
- Loxo Oncology Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D231/38. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).